ArticleMolecular therapy. Advances2026
DNA damage/p53, innate immune, and unfolded protein responses are activated in primate liver after toxic, high-dose AAV-SMN1 delivery.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dose makes the poison: Mechanisms of cytotoxicity of high-dose AAV vectors.Molecular therapy. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Administration of high doses of a recombinant adeno-associated virus vector expressing the SMN1 protein (AAV-SMN1) can cause severe acute liver injury and death in non-human primates (NHPs) and, in rare cases, in patients. This study aimed to elucidate the molecular mechanisms underlying AAV-SMN1-induced liver damage. Transcriptomic analysis was performed using RNA-sequencing data from the livers of NHPs and rats receiving escalating doses of AAV-SMN1 and sacrificed 4-5 days later. Profound, dose-dependent transcriptomic changes were observed in NHPs. At the toxic, highest doses, there was significant upregulation of genes involved in the DNA damage/p53 response, pro-apoptotic unfolded protein response (UPR), and innate immune response, along with downregulation of genes associated with hepatocyte metabolic pathways. In contrast, NHPs receiving low doses and rats showed transcriptional changes indicative of antiviral pathway activation and T cell responses. In high-dose NHPs, SMN1 transgene levels correlated positively with pro-apoptotic UPR genes and inversely with hepatocyte identity genes. Here, we propose that AAV-induced hepatotoxicity involves cell-intrinsic mechanisms, such as UPR activation and the DNA damage/p53 response, which, along with the activation of innate immune responses, contribute to hepatocyte death. Targeting these pathways may offer a promising strategy for safer AAV-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.